跳至主要内容
临床试验/NCT01341522
NCT01341522撤回3 期

Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System

LivaNova0 个研究点开始时间: 2012年1月最近更新:
适应症

试验速览

阶段
3 期
状态
撤回
发起方
LivaNova
主要终点
assess the pacing system-, MRI- and implant procedure-related complication-free rate

研究概览

简要总结

Permanent cardiac pacemakers have represented a contraindication to Magnetic Resonance Imaging (MRI). Strong static, gradient and radiofrequency fields used for MRI are thought to be detrimental to pacemaker function and possibly cause harm to patients undergoing MRI examinations. A previous study has shown that MRI is indicated in 17% of all patients with pacemakers within 12 months of device placement , which demonstrates the need of practical, safe approach for performing MRI on pacemaker patients. A new Reply MR-conditional pacing system is developed by Sorin Group for safe use in the MRI environment. The new pacing system is composed by the Reply pacemaker and the Filtrea bradycardia pacing leads. This study intends to demonstrate the safety and the efficacy in the MRI environment of the Sorin Group Reply MR-conditional pacing system.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who are candidates for dual-chamber pacemaker primo-implantation
  • Patients who have indication for implantation of a dual-chamber pacemaker according to the American College of Cardiology and the American Heart Association
  • Patients who are able and willing to undergo elective MRI scanning
  • Patients who are scheduled for implant of a Reply DR pacemaker and Filtrea lead(s) only
  • Patients who provided signed and dated informed consent

排除标准

  • Non MR-compatible device or material implant
  • Chronic atrial fibrillation (for atrial lead evaluation)
  • Incessant ventricular tachyarrhythmia (for ventricular lead evaluation)
  • Inability to understand the purpose of the study or refusal to co-operate
  • Unavailability for scheduled follow-ups at the implanting centre
  • Already included in another clinical study that could affect the results of this study
  • Inability or refusal to provide informed consent
  • Patient is minor (less than 18-year old)
  • Patient is pregnant (women of childbearing potential should have a negative pregnancy test prior to enrolment);
  • Patient has life expectancy of less than 1 year
  • Patient is forfeiture of freedom or under guardianship
  • Any patient to whom a contra-indication from device and lead labeling applies

结局指标

主要结局

assess the pacing system-, MRI- and implant procedure-related complication-free rate

时间窗: 1 month

assess atrial and ventricular lead-related complication-free rate

时间窗: 3 months

compare the changes in atrial and ventricular pacing thresholds before and after MRI, between MRI and control groups

时间窗: 3 months

compare the changes in atrial and ventricular sense amplitude after MRI between MRI and control groups

时间窗: 3 months

次要结局

  • Summarize atrial and ventricular electrical performances(3 months)
  • Summarize all implant procedure, pacing system- and MRI procedure-related adverse events(12 months)
  • Summarize atrial and ventricular lead handling(2 weeks)

研究者

发起方
LivaNova
申办方类型
Industry
责任方
Sponsor

相似试验